

\*\*\*\*Published February 2023\*\*\*\*

## MarketVIEW: RSV older adult, elderly vaccines (CAT: VAMV088)

<b>Product Name</b>	:	<b>MarketVIEW: RSV older adult, elderly vaccines</b>
<b>Description</b>	:	Global vaccine commercial opportunity assessment
<b>Contents</b>	:	Executive presentation (~300 slides .pdf) + forecast model(s) (.xls)
<b>Therapeutic Area</b>	:	<b>RSV vaccines</b>
<b>Publication date</b>	:	February 2023
<b>Catalogue No</b>	:	VAMV088

### Background

**Human respiratory syncytial virus (RSV)** is a common respiratory which is now recognized as an important pathogen in adults, especially the elderly. In adults, about 1.5m episodes of RSV-ARI occur in industrialized countries. Globally, 336,000 hospital admissions and 14,000 in-hospital deaths have been estimated although the true burden is believed to be higher (Shi T et al., 2020). In the USA 60-160,000 hospitalizations are estimated for persons >65 yrs with around 6-10,000 deaths (CDC, RSV-NET cited figures), again with wide variance in estimates. **Cardiovascular, chronic lung and diabetes** are common underlying conditions in persons (>18 yrs) hospitalized with RSV infection with in-hospital mortality at ~12% (Shi T et al., 2022). There is no specific treatment for RSV infection and for those adults who require hospitalization, supportive therapy is still the mainstay of care.

The **RSV older adult, elderly vaccine** development field is one of the most active in the industry with several pivotal Phase 3 studies now ongoing, 3 of which have met pre-specified primary endpoints in 2023. Major companies such as **Pfizer**, PF-06928316, **GSK Biologicals**, GSK3844766A, **Janssen NV**, Ad26.RSV.preF, **ModernaTX**, mRNA-1345, **Sanofi Pasteur**, CL-0059, CL-0137 and **Bavarian Nordic**, MVA-BN-RSV have a range of vaccine approaches including mRNA technologies which could facilitate future combination pan-respiratory vaccines, already emerging in seasonal influenza and COVID-19 (mRNA-1073, 1230, 1045). The **US ACIP** committee met in October 2022 to discuss the Pfizer and GSK datasets and is expected to make a policy decision in June 2023, post FDA PDUFA dates in May 2023 for those manufacturers who have already filed regulatory submissions.

This **MarketVIEW** product is a comprehensive Executive Presentation (~300 slides, .pdf) and **interactive** MS-Excel forecast model(s) which investigate the scenario-based commercial potential of RSV older adult elderly vaccines profiles to 2037. 52 countries are included (public/private sector) where the impact of different country specific pricing analogues, at risk stratifications and cohort target ranges can be explored. The new 2023 model can accommodate **both yearly and 2-yearly schedules** and the potential impact of combination products.

This report contains a thorough review of disease background/epidemiology/cost-effectiveness studies along with vaccinology/R&D competitive landscape with an emphasis on future **product differentiators**, product longevity & company specific revenues/share per USA, EU, Developed ROW and Emerging markets. It is ideally suited to organisations wishing to access an up-to-date advanced global quantification of the RSV older adult, elderly vaccines future market

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to RSV vaccines and monoclonals in each respective market. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised including SARS-CoV-2 and seasonal influenza vaccines.

### PRODUCT CONTENTS:

**Published February 2023 (CAT No: VAMV088)**

\*\*\*\*This product is a [summary presentation \(.pdf\)](#), [an MS-workbook \(.xls\)](#)

#### Contents – Summary presentation (.pdf)



Contents

Author's notes

#### Executive summary

**[SECTION 1]** RSV older adult, elderly vaccines: commercial model key outputs

**[SECTION 2]** RSV: disease background

**[SECTION 3]** RSV: economic burden/latest CE studies

**[SECTION 4]** RSV older adult, elderly vaccines: R&D pipeline/competitor activity

**[SECTION 5]** RSV older adult, elderly vaccines: CDC US ACIP workgroup, manufacturer discussions

**[SECTION 6]** RSV older adult, elderly vaccines: modelling commercial potential

**[SECTION 7]** RSV older adult, elderly vaccines: covering of RSV vaccines, earlier stage data

References/bibliography

About **VacZine Analytics**

Disclaimer

**SNAPSHOT**

**PAGES: >300 slides fully referenced/sourced. Available in .pdf form**

#### Contents – MS-Excel workbook (.xls)



United States [5 target product profiles, public and private sector]

Canada

UK

France

Germany

Italy

Spain

Other Europe 1 & 2

Brazil

India

China

Russia

Mexico

Australia, Japan, South Korea

PAHO (other)

International (other)

**PRODUCT COST:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$contact us**/ GBP **£contact us**# (Global license only)\*

\*Global = North America, Europe or ROW (non-exclusive, non-transferable license)

For orders in the UK, VAT at 20% will be added to final invoice total

# - *indicative prevailing rate will be applied on date of transaction*

**HOW TO ORDER:**

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com) This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.




**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and the “**spiral logo**” are UK Registered Trademarks, 2009



## **BIBLIOGRAPHY**

➤ 400 References – available upon request



**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired while providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**

A division of Assay Advantage Ltd  
Warren (Carlton) House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 927049  
E-mail: [info@vaczine-analytics.com](mailto:info@vaczine-analytics.com)



## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and “the spiral logo” are UK Registered Trademarks, 2009



*Since 2007*

